Isogaine

Mepivacaine Hydrochloride, the active ingredient in Isogaine, is a local anesthetic presented as a sterile solution for intramuscular and subcutaneous use. It provides reversible nerve blockade to facilitate painless minor surgical, dental, and diagnostic procedures in adult patients.

GNH USA supplies Isogaine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mepivacaine Hydrochloride is a local anesthetic used to achieve regional nerve blockade in various minor procedures.

- Minor surgical procedures: provides local anesthesia to enable pain‑free surgery. - Dental procedures: enables painless extractions, restorations and other dental work. - Diagnostic or therapeutic regional anesthesia: creates temporary numbness for procedures requiring regional nerve block.

Adverse reactions may occur following administration of mepivacaine.

Common Side Effects: - Burning or stinging at the injection site - Tingling or numbness that persists briefly after the procedure - Light‑headedness or dizziness - Nausea or mild vomiting - Transient hypotension - Headache

Serious or Rare Side Effects: - Allergic reactions including rash, itching or anaphylaxis - Cardiovascular collapse or severe hypotension - Seizures or central nervous system toxicity - Prolonged or unexpected numbness - Methemoglobinemia - Cardiac arrhythmias such as ventricular tachycardia

Careful assessment and monitoring are required when using mepivacaine.

- Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: use cautiously in patients with conduction disorders or significant heart disease. - Dosage limits: adhere to maximum recommended dose to avoid systemic toxicity. - Pregnancy and lactation: evaluate risk–benefit; data are limited. - Elderly or hepatic impairment: consider dose reduction. - Store at ambient temperature: keep in original container, protect from light and moisture.

Mepivacaine may interact with other drugs that affect cardiac or central nervous system function.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): increase plasma levels and toxicity. - Beta‑blockers: may potentiate cardiovascular depression. - MAO inhibitors: risk of enhanced hypotension.

Moderate Interactions (Monitor Closely): - Other local anesthetics: cumulative toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids): may augment sedation. - Diuretics: may alter plasma concentration of the anesthetic.